000			03269nam a22004335i 4500
001			978-1-4614-1216-8
003			DE-He213
005			20140220083241.0
007			cr nn 008mamaa
008			111111s2012 xxu| s |||| 0|eng d
020			_a9781461412168 _9978-1-4614-1216-8
024	7		_a10.1007/978-1-4614-1216-8 _2doi
050		4	_aRC261-271
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a614.5999 _223
100	1		_aFrank, David A. _eeditor.
245	1	0	_aSignaling Pathways in Cancer Pathogenesis and Therapy _h[electronic resource] / _cedited by David A. Frank.
264		1	_aNew York, NY : _bSpringer New York, _c2012.
300			_aVIII, 148 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aSignaling Pathways in Cancer:  21st Century Approaches to Cancer Therapy -- Current And Next Generation Antimitotic Therapies In Cancer -- DNA Damage Checkpoint Signaling Pathways in Human Cancer -- Non-Receptor Tyrosine Kinases and their Roles in Cancer -- The Hedgehog Signaling Pathway in Cancer Pathogenesis and Therapy -- Wnt Signaling in Cancer Pathogenesis and Therapeutics -- STAT Signaling in the Pathogenesis and Treatment of Cancer -- Protein Therapeutics in Oncology.- Index   .
520			_aSince the 1940s, the treatment of advanced cancer has been based on administering maximal doses of non-specifically toxic drugs in the hope that cancer cells would be killed more effectively than normal cells.  While this is occasionally successful, for most common cancers only a minority of patients experience any meaningful benefit.  Unfortunately, nearly all treated patients experience toxicities, which range from unpleasant to life threatening.  In recent years, however, our understanding of the molecular underpinnings of cancer has increased enormously.  We now have a much deeper understanding of how intracellular signaling pathways that control critical cellular functions can become subverted by the genetic alterations arising in a cancer cell.  In fact, we are now in a position to use this knowledge to design rational targeted therapeutic approaches that hold the promise of much greater efficacy with fewer side effects.  In this volume, oncologists and scientists from academia, government, and industry have come together to provide insight into strategies to modulate signaling pathways, which are currently being translated from the laboratory to the clinic.  These advances will hopefully usher in a new era in the treatment of cancer patients, and thus the goal of this volume is both to inform those interested in this field, and to inspire further contributions in this cutting edge area.
650		0	_aMedicine.
650		0	_aOncology.
650		0	_aToxicology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aPharmacology/Toxicology.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781461412151
856	4	0	_uhttp://dx.doi.org/10.1007/978-1-4614-1216-8
912			_aZDB-2-SBL
999			_c101018 _d101018